Pyrazinamide — on the antituberculosis drug frontline

1. Mitchison, D.A. The Garrod Lecture. Understanding the chemotherapy of tuberculosis — current problems. J. Antimicrob. Chemo. 29, 477−493 (1992). | ISI | ChemPort |
2. McDermott, W. & Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70, 748−754 (1954). | PubMed  | ISI | ChemPort |
3. McCune, R.M., Tompsett, R. & McDermott, W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J. Exp. Med. 104, 763−803 (1956). | PubMed  | ISI | ChemPort |
4. Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219−225 (1985). | Article | PubMed  | ISI | ChemPort |
5. Konno, K., Feldmann, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461−469 (1967). | PubMed  | ISI | ChemPort |
6. Cynamon, M.H. et al. Pyrazinoic acid esters with broad spectrum in vitro anti-mycobacterial activity. J. Med. Chem. 38, 3902−3907 (1995). | PubMed  | ISI | ChemPort |
7. Crowle, A.J., Dahl, R., Ross, E. & May, M.H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 59, 1823−1831 (1991). | PubMed  | ISI | ChemPort |
8. Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to antituberculous drug pyrazinamide in tubercle bacillus. Nature Med. 2, 662−667 (1996). | Article | PubMed  | ISI | ChemPort |
9. Brander, E. A simple way of detecting pyrazinamide resistance. Tubercle, 53, 128−131 (1972). | Article | PubMed  | ChemPort |
10. Cole, S.T. Mycobacterium tuberculosis: Drug resistance mechanisms. Trends Microbiol. 2, 411−415 (1994). | Article | PubMed  | ChemPort |

	Top

	Top